NCT05397093 2026-04-15
ITIL-306 in Advanced Solid Tumors
Instil Bio
Phase 1 Terminated
Clinical Trials
27 trialsNCT03519178 2025-11-14
A Study of PF-06873600 in People With Cancer
Pfizer
Phase 1/2 Terminated
NCT05317078 2025-10-08
A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications
Amgen
Phase 1 Terminated
NCT05870748 2025-09-23
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc.
Phase 2/3 Terminated
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT05274451 2025-07-01
A Study to Investigate LYL797 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
Phase 1 Terminated
NCT05891197 2025-07-01
START
Lyell Immunopharma, Inc.
Terminated
NCT05261490 2024-11-19
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pfizer
Phase 1/2 Terminated
NCT04493619 2024-11-04
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Opna Bio LLC
Phase 1/2 Terminated
NCT06068738 2024-09-26
EXCYTE-1
Exscientia AI Limited
Terminated
NCT04182516 2024-09-19
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
Nerviano Medical Sciences
Phase 1 Terminated
NCT05001282 2024-08-07
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Elucida Oncology
Phase 1/2 Terminated
NCT05769959 2024-07-09
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT04726332 2024-05-14
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
Exelixis
Phase 1 Terminated
NCT03330405 2023-10-13
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT03824704 2023-06-12
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
pharmaand GmbH
Phase 2 Terminated
NCT01018563 2021-12-08
An Open Label Extension Study of the Efficacy of MORAb-003
Morphotek
Phase 2 Terminated
NCT02947152 2020-12-08
HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma
Novartis
Phase 1 Terminated
NCT02943317 2019-04-30
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
Verastem, Inc.
Phase 1 Terminated
NCT01281254 2017-12-02
TRINOVA-2
Amgen
Phase 3 Terminated
NCT01521143 2016-12-14
CANVAS
Prima BioMed Ltd
Phase 2 Terminated
NCT02107378 2016-11-30
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Terminated
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00003880 2015-04-16
Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT00516841 2012-08-23
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Facet Biotech
Phase 2 Terminated
NCT00034138 2007-12-18
A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma
Unither Pharmaceuticals
Phase 1/2 Terminated
NCT00034372 2007-12-18
Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
Unither Pharmaceuticals
Phase 2 Terminated